Jan van Lunzen

Summary

Affiliation: University Medical Center Hamburg-Eppendorf
Country: Germany

Publications

  1. doi Gene therapy strategies: can we eradicate HIV?
    Jan van Lunzen
    Infectious Diseases Unit, University Medical Center Hamburg Eppendorf, Martinistr 52, 20246 Hamburg, Germany
    Curr HIV/AIDS Rep 8:78-84. 2011
  2. ncbi Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
    Jan van Lunzen
    Infectious Diseases Unit, University Medical Centre Hamburg Eppendorf, Martinistrasse 52, Hamburg, Germany
    Lancet Infect Dis 12:111-8. 2012
  3. pmc Assessment of the range of the HIV-1 infectivity enhancing effect of individual human semen specimen and the range of inhibition by EGCG
    Philip Hartjen
    Infectious Diseases Unit, I, Department of Internal Medicine, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20251 Hamburg, Germany
    AIDS Res Ther 9:2. 2012
  4. doi Sustained virological response after early antiviral treatment of acute hepatitis C virus and HIV coinfection
    Julian Schulze zur Wiesch
    Department of Medicin, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Clin Infect Dis 49:466-72. 2009
  5. doi Decreased frequency of CD73+CD8+ T cells of HIV-infected patients correlates with immune activation and T cell exhaustion
    Ilona Tóth
    1 Section Infectious Diseases, University Medical Center Hamburg Eppendorf, Martinistr 52, 20246 Hamburg, Germany
    J Leukoc Biol 94:551-61. 2013
  6. doi Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease
    Christian Hoffmann
    Infektionsmedizinisches Centrum Hamburg, Hamburg, Germany
    Blood 118:3499-503. 2011
  7. ncbi Adoptive transfer of syngeneic T cells in HIV-1 discordant twins indicates rapid regulation of T-cell homeostasis
    Christian Hoffmann
    University Medical Centre Hamburg Eppendorf, Hamburg, Germany
    Br J Haematol 136:641-8. 2007
  8. doi Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma
    Alexander Zoufaly
    Infectious Diseases Unit, Department of Medicine, University Medical Center Hamburg Eppendorf, Germany
    J Infect Dis 200:79-87. 2009
  9. pmc Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease
    Julian Schulze zur Wiesch
    Infectious Disease Unit, Department of Medicine, University Medical Center Hamburg Eppendorf, Martinistr 52, 20246 Hamburg, Germany
    J Virol 85:1287-97. 2011
  10. pmc Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients
    Christoph Wyen
    Department of Internal Medicine, University of Cologne, Koln, Germany
    J Antimicrob Chemother 61:914-8. 2008

Collaborators

Detail Information

Publications18

  1. doi Gene therapy strategies: can we eradicate HIV?
    Jan van Lunzen
    Infectious Diseases Unit, University Medical Center Hamburg Eppendorf, Martinistr 52, 20246 Hamburg, Germany
    Curr HIV/AIDS Rep 8:78-84. 2011
    ..Indeed the intriguing finding that HIV seems to be eradicated in an individual case study after stem cell transplantation with a mutant coreceptor (CCR5 delta 32 deletion) underlines the proof of the concept...
  2. ncbi Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
    Jan van Lunzen
    Infectious Diseases Unit, University Medical Centre Hamburg Eppendorf, Martinistrasse 52, Hamburg, Germany
    Lancet Infect Dis 12:111-8. 2012
    ..SPRING-1 is an ongoing study designed to select a dose for phase 3 assessment. We present data from preplanned primary and interim analyses...
  3. pmc Assessment of the range of the HIV-1 infectivity enhancing effect of individual human semen specimen and the range of inhibition by EGCG
    Philip Hartjen
    Infectious Diseases Unit, I, Department of Internal Medicine, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20251 Hamburg, Germany
    AIDS Res Ther 9:2. 2012
    ..However, the reasons for the variability in the efficacy of the abrogation of semen-mediated enhancement of HIV-1 infectivity and EGCG efficacy have to be elucidated before therapeutic trials can be conducted...
  4. doi Sustained virological response after early antiviral treatment of acute hepatitis C virus and HIV coinfection
    Julian Schulze zur Wiesch
    Department of Medicin, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Clin Infect Dis 49:466-72. 2009
    ..We present detailed clinical and immunological analysis of 3 individuals after concomitant infection with acute HCV and primary HIV...
  5. doi Decreased frequency of CD73+CD8+ T cells of HIV-infected patients correlates with immune activation and T cell exhaustion
    Ilona Tóth
    1 Section Infectious Diseases, University Medical Center Hamburg Eppendorf, Martinistr 52, 20246 Hamburg, Germany
    J Leukoc Biol 94:551-61. 2013
    ..These data indicate that down-regulation of CD73 on CD8(+) T cells correlates with immune activation and leads to functional deficits in HIV infection. ..
  6. doi Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease
    Christian Hoffmann
    Infektionsmedizinisches Centrum Hamburg, Hamburg, Germany
    Blood 118:3499-503. 2011
    ....
  7. ncbi Adoptive transfer of syngeneic T cells in HIV-1 discordant twins indicates rapid regulation of T-cell homeostasis
    Christian Hoffmann
    University Medical Centre Hamburg Eppendorf, Hamburg, Germany
    Br J Haematol 136:641-8. 2007
    ..The clearance kinetics of the transfused cells from peripheral blood indicates a very rapid regulation of T-cell homeostasis in HIV infection...
  8. doi Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma
    Alexander Zoufaly
    Infectious Diseases Unit, Department of Medicine, University Medical Center Hamburg Eppendorf, Germany
    J Infect Dis 200:79-87. 2009
    ..We assessed the predictive role of cumulative HIV viremia and other risk factors in the development of AIDS-related non-Hodgkin lymphoma...
  9. pmc Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease
    Julian Schulze zur Wiesch
    Infectious Disease Unit, Department of Medicine, University Medical Center Hamburg Eppendorf, Martinistr 52, 20246 Hamburg, Germany
    J Virol 85:1287-97. 2011
    ..The data presented here reconcile the seemingly contradictory results of previous studies looking at Tregs in HIV and highlight the complexity of Treg-mediated immunoregulation during human viral infections...
  10. pmc Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients
    Christoph Wyen
    Department of Internal Medicine, University of Cologne, Koln, Germany
    J Antimicrob Chemother 61:914-8. 2008
    ..The aim of this study was to investigate the frequency of CYP2B6 polymorphisms (according to ethnicity) and the influence of heterozygosity and homozygosity on plasma concentrations of efavirenz and nevirapine...
  11. ncbi Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus
    Jan van Lunzen
    Infectious Diseases Unit, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Mol Ther 15:1024-33. 2007
    ..In conclusion, the transfer of gene-modified cells was safe, led to sustained levels of gene marking, and may improve immune competence in HIV-infected patients with advanced disease and multidrug-resistant virus...
  12. pmc Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohort
    Matthias Stoll
    Infectious Diseases Unit, Medical University, Hanover, Germany
    PLoS ONE 6:e23946. 2011
    ..The second aim was to develop potential cost saving strategies by modelling different treatment scenarios...
  13. ncbi Stereoselective synthesis of D- and L-carbocyclic nucleosides by enzymatically catalyzed kinetic resolution
    Miriam Mahler
    Organic Chemistry, Department of Chemistry, Faculty of Sciences, University of Hamburg, Hamburg, Germany
    Chemistry 18:11046-62. 2012
    ..However, against the wild-type virus strain NL4/3, d4T was found to be more-active than D-carba-dT...
  14. ncbi Prevalence and determinants of virological failure in HIV-infected children on antiretroviral therapy in rural Cameroon: a cross-sectional study
    Alexander Zoufaly
    Department of Medicine I, Infectious Diseases Unit, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Antivir Ther 18:681-90. 2013
    ..We aimed to identify prevalence and determinants of virological failure in HIV-infected children treated under programmatic conditions...
  15. ncbi How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infection
    Jan van Lunzen
    University Medical Centre Hamburg Eppendorf, Heinrich Pette Institute for Experimental Virology and Immunology, Hamburg, Germany
    Eur J Med Res 12:435-40. 2007
    ....
  16. ncbi Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection
    Malte H Wehmeyer
    I, Medizinische Klinik und Poliklinik, Universitatsklinikum Hamburg Eppendorf, Martinistr, 52, Hamburg 20246, Germany
    BMC Gastroenterol 14:87. 2014
    ..There is only limited data regarding the safety and efficacy in a "real-life" cohort...
  17. ncbi Virological rebound and its consequences during treatment interruption
    Jan van Lunzen
    aUniversity Medical Center Hamburg Eppendorf and Heinrich Pette Institute for Experimental Virology and Immunology, Germany bInstitute for Interdisciplinary Medicine, Hamburg, Germany
    Curr Opin HIV AIDS 2:1-5. 2007
    ..SUMMARY: Treatment interruptions cannot be recommended in HIV-infected patients outside clinical trials, especially when profound immune deficiency is found to be preexisting...
  18. ncbi Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial)
    Hans Jurgen Stellbrink
    Department of Medicine, Eppendorf University, Hamburg, Germany
    AIDS 16:1479-87. 2002
    ..The effect of interleukin-2 (IL-2) in combination with antiretroviral therapy on HIV-1 replication and reservoirs was investigated...